FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2595401521> ?p ?o ?g. }

• W2595401521 endingPage "4593" @default.
• W2595401521 startingPage "4593" @default.
• W2595401521 abstract "Abstract Background: Acute graft versus host disease (aGVHD) is the leading cause of morbidity and mortality following allogenic hematopoietic cell transplantation (HCT). Corticosteroids are the first line treatment although <50% of patients with severe aGVHD (grades III-IV) achieve durable remissions. Monoclonal antibodies (mAb) are often used as second line agents for steroid refractory aGVHD (SR-aGVHD) (Patriarca et. al.; 2004). However, data regarding their tolerability and efficacy is retrospective and limited. We carried out this study to assess the clinical outcomes related to mAb therapy (Infliximab and Tocilizumab) for SR-aGVHD. Methods: Patients with SR-aGVHD that received therapy with either Infliximab or Tocilizumab between January 2003 and May 2016 were retrospectively identified. Clinical grading of aGVHD was per the Glucksberg criteria (Glucksberg et. al.; 1974). SR-aGVHD was defined as any grade progression within 3 days or failure to achieve at least one grade improvement within 7 days of initiation of systemic steroids. Infliximab and Tocilizumab were administered intravenously at 10mg/kg and 8mg/kg weekly for a total of 4 doses, respectively. Clinical response was evaluated at 4 weeks and 12 weeks post mAb treatment. Complete response (CR) was defined as sustained resolution of all clinical signs of aGVHD; partial response (PR) was defined as overall improvement of 1 or more grades; no response (NR) was defined as neither improvement nor worsening of the overall aGVHD grade. Overall response (OR) was defined as either CR or PR. Overall survival (OS) was calculated from the first day of mAb treatment until death or last available follow up. Results: Forty-three patients (median age 54, range 29-74 years; male 67%) with severe SR- aGVHD were included in the study. Of these, 35 (81%) received Infliximab for a median of 4 (range 1-6) cycles and 8 (19%) received Tocilizumab for a median of 3 (range 1-4) cycles. Both groups were comparable with regards to age, gender, conditioning regimen, graft source, degree of HLA match, ABO blood group, CMV incompatibility, and GVHD prophylaxis regimens. Only differences seen were a higher proportion of unrelated donor (p = 0.004) and cord blood HCT (p = 0.031) in the Tocilizumab group. Twenty (57%) of 35 patients treated with Infliximab and 6 (75%) of 8 patients treated with Tocilizumab had an overall aGVHD grade of IV prior to initiation of mAb therapy (p = 0.44). Organ specific distribution and severity of aGVHD are described in table 1. At 4 weeks post mAb therapy, 17 (40%) patients had an OR, 7 (16%) had no response, and 19 (44%) had died. Twenty-six (60%) patients died at 12 weeks, with OR and no response observed in 9 (21%) and 8 (19%) patients, respectively (table 2). Overall response for Tocilizumab versus Infliximab was comparable at 4 weeks (38% vs. 40%; p = 1.0) and at 12 weeks (38% vs. 17%; p = 0.33). Outcomes per aGVHD grade and gastrointestinal-specific stage at 4 weeks and 12 weeks are shown in figures 1-A and 1-B, with organ specific responses shown in figures 1-C and 1-D, respectively. The estimated median OS was 41 (range 4-3837) days for patients treated with Infliximab and 60 (range 10-756) days for those treated with Tocilizumab (p = 0.48). Disease relapse occurred in 5 (11%) patients treated with Infliximab and in none (0%) treated with Tocilizumab (p = 0.56). Thirty-four (79%) patients had infectious complications during and up to one month after mAb therapy. These included 31 (72%) patients with bacterial blood stream infection and 10 (23%) with invasive fungal infections. Overall, infectious complications were comparable (Infliximab - 83% vs. Tocilizumab - 63%; p = 0.33). CMV reactivation occurred in 11 (31%) and in 2 (25%) patients who were treated with Infliximab and Tocilizumab, respectively (p = 1.0). Given the retrospective nature of the study and the concomitant presence of aGVHD, it was difficult to attribute and grade gastrointestinal and hepatobiliary side effects. Conclusions: The use of anti-inflammatory monoclonal antibody therapy in patients with steroid refractory acute GVHD is associated with significant infectious complications (~80%) and poor response rates (~20% at 12 weeks). Current data, limited by a small sample size, does not show any advantages of using Tocilizumab over Infliximab or vice versa. Prospective clinical trials addressing this question are needed. Disclosures No relevant conflicts of interest to declare." @default.
• W2595401521 created "2017-03-23" @default.
• W2595401521 creator A5012781424 @default.
• W2595401521 creator A5024011788 @default.
• W2595401521 creator A5027546805 @default.
• W2595401521 creator A5048300954 @default.
• W2595401521 creator A5064856519 @default.
• W2595401521 creator A5067492340 @default.
• W2595401521 creator A5072463255 @default.
• W2595401521 creator A5076034488 @default.
• W2595401521 creator A5084606047 @default.
• W2595401521 creator A5085360755 @default.
• W2595401521 date "2016-12-02" @default.
• W2595401521 modified "2023-10-16" @default.
• W2595401521 title "Clinical Outcomes Related to the Use of Monoclonal Antibody Therapy for Steroid Refractory Acute Graft-Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation" @default.
• W2595401521 doi "https://doi.org/10.1182/blood.v128.22.4593.4593" @default.
• W2595401521 hasPublicationYear "2016" @default.
• W2595401521 type Work @default.
• W2595401521 sameAs 2595401521 @default.
• W2595401521 citedByCount "0" @default.
• W2595401521 crossrefType "journal-article" @default.
• W2595401521 hasAuthorship W2595401521A5012781424 @default.
• W2595401521 hasAuthorship W2595401521A5024011788 @default.
• W2595401521 hasAuthorship W2595401521A5027546805 @default.
• W2595401521 hasAuthorship W2595401521A5048300954 @default.
• W2595401521 hasAuthorship W2595401521A5064856519 @default.
• W2595401521 hasAuthorship W2595401521A5067492340 @default.
• W2595401521 hasAuthorship W2595401521A5072463255 @default.
• W2595401521 hasAuthorship W2595401521A5076034488 @default.
• W2595401521 hasAuthorship W2595401521A5084606047 @default.
• W2595401521 hasAuthorship W2595401521A5085360755 @default.
• W2595401521 hasConcept C121332964 @default.
• W2595401521 hasConcept C126322002 @default.
• W2595401521 hasConcept C141071460 @default.
• W2595401521 hasConcept C142424586 @default.
• W2595401521 hasConcept C197934379 @default.
• W2595401521 hasConcept C203014093 @default.
• W2595401521 hasConcept C2777138892 @default.
• W2595401521 hasConcept C2777178219 @default.
• W2595401521 hasConcept C2777408962 @default.
• W2595401521 hasConcept C2778375690 @default.
• W2595401521 hasConcept C2779134260 @default.
• W2595401521 hasConcept C2779972918 @default.
• W2595401521 hasConcept C2911091166 @default.
• W2595401521 hasConcept C71924100 @default.
• W2595401521 hasConcept C87355193 @default.
• W2595401521 hasConcept C90924648 @default.
• W2595401521 hasConceptScore W2595401521C121332964 @default.
• W2595401521 hasConceptScore W2595401521C126322002 @default.
• W2595401521 hasConceptScore W2595401521C141071460 @default.
• W2595401521 hasConceptScore W2595401521C142424586 @default.
• W2595401521 hasConceptScore W2595401521C197934379 @default.
• W2595401521 hasConceptScore W2595401521C203014093 @default.
• W2595401521 hasConceptScore W2595401521C2777138892 @default.
• W2595401521 hasConceptScore W2595401521C2777178219 @default.
• W2595401521 hasConceptScore W2595401521C2777408962 @default.
• W2595401521 hasConceptScore W2595401521C2778375690 @default.
• W2595401521 hasConceptScore W2595401521C2779134260 @default.
• W2595401521 hasConceptScore W2595401521C2779972918 @default.
• W2595401521 hasConceptScore W2595401521C2911091166 @default.
• W2595401521 hasConceptScore W2595401521C71924100 @default.
• W2595401521 hasConceptScore W2595401521C87355193 @default.
• W2595401521 hasConceptScore W2595401521C90924648 @default.
• W2595401521 hasIssue "22" @default.
• W2595401521 hasLocation W25954015211 @default.
• W2595401521 hasOpenAccess W2595401521 @default.
• W2595401521 hasPrimaryLocation W25954015211 @default.
• W2595401521 hasRelatedWork W1793302197 @default.
• W2595401521 hasRelatedWork W1996887190 @default.
• W2595401521 hasRelatedWork W2031308315 @default.
• W2595401521 hasRelatedWork W2130010378 @default.
• W2595401521 hasRelatedWork W2157982523 @default.
• W2595401521 hasRelatedWork W2311410140 @default.
• W2595401521 hasRelatedWork W2378369323 @default.
• W2595401521 hasRelatedWork W2528057197 @default.
• W2595401521 hasRelatedWork W2801467670 @default.
• W2595401521 hasRelatedWork W3176439830 @default.
• W2595401521 hasVolume "128" @default.
• W2595401521 isParatext "false" @default.
• W2595401521 isRetracted "false" @default.
• W2595401521 magId "2595401521" @default.
• W2595401521 workType "article" @default.